Literature DB >> 29860548

Comparison of iohexol and iodixanol induced nephrotoxicity, mitochondrial damage and mitophagy in a new contrast-induced acute kidney injury rat model.

Wei Cheng1, Fei Zhao1, Cheng-Yuan Tang1, Xu-Wei Li1, Min Luo1, Shao-Bin Duan2.   

Abstract

Recent progress in angiography and interventional therapy has revived interest in comparison of nephrotoxicity of low-or iso-osmolar contrast media, but detailed mechanisms and effective treatments of contrast-induced acute kidney injury (CI-AKI) remain elusive. We established a new model of CI-AKI and compared the nephrotoxicity of iohexol and iodixanol with a focus on renal oxidative stress, mitochondrial damage and mitophagy. Our results showed that 48-h dehydration plus furosemide injection before iohexol administration successfully induced CI-AKI in rats. Compared with iodixanol, iohexol induced a greater decrease in renal function, more severe morphological damage and mitochondrial ultrastructural changes, an increased number of apoptotic cells, decreased antioxidative enzymes with activation of NLRP3 inflammasome in renal tissue. Renal contrast media kinetics showed the immediate excretion of iohexol and the transient renal accumulation of iodixanol. Plasma mtDNA Tc numbers were positively correlated with markers of renal mitochondrial disruption but negatively correlated with the level of serum creatinine and the score of tubular injury. Of note, iodixanol appeared to induce a stronger activation of mitophagy than iohexol, evidenced by greater protein levels of LC3II and PINK1/Parkin in the renal tissue of iodixanol-treated rats. Taken together, our results indicate that iohexol induced more severe nephrotoxicity than iodixanol in vivo due to apoptosis, destruction of antioxidative defense machinery, activation of NLRP3 inflammasome, mitochondrial damage and mitophagy. Plasma mtDNA may serve as a biological marker for renal mitochondrial disruption and damage in CI-AKI. Antioxidative defense and mitophagy are involved in the process of CI-AKI and may be promising targets of therapies.

Entities:  

Keywords:  Acute kidney injury; Contrast media; Mitochondrial damage; Mitophagy; Nephrotoxicity; Oxidative stress

Mesh:

Substances:

Year:  2018        PMID: 29860548     DOI: 10.1007/s00204-018-2225-9

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  12 in total

1.  Meta-analysis on allopurinol preventive intervention on contrast-induced acute kidney injury with random controlled trials: PRISMA.

Authors:  Guang Ma; Guoliang Wang; Dongbin Xiao; Wei Teng; Xuezhi Hui; Guang Ma
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

2.  Stanniocalcin-1 Alleviates Contrast-Induced Acute Kidney Injury by Regulating Mitochondrial Quality Control via the Nrf2 Pathway.

Authors:  Fei Zhao; Li-Xin Feng; Qian Liu; Hong-Shen Wang; Cheng-Yuan Tang; Wei Cheng; Yin-Hao Deng; Xi Wu; Ping Yan; Xiang-Jie Duan; Jin-Cheng Peng; Shao-Bin Duan
Journal:  Oxid Med Cell Longev       Date:  2020-04-12       Impact factor: 6.543

Review 3.  Mitophagy in Acute Kidney Injury and Kidney Repair.

Authors:  Ying Wang; Juan Cai; Chengyuan Tang; Zheng Dong
Journal:  Cells       Date:  2020-02-01       Impact factor: 6.600

4.  15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury.

Authors:  Byeong Woo Kim; Hye Jung Kim; Sun-Hee Kim; Hyung Joo Baik; Mi Seon Kang; Dong-Hyun Kim; Sanford D Markowitz; Sun Woo Kang; Ki Beom Bae
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

5.  Paricalcitol Attenuates Contrast-Induced Acute Kidney Injury by Regulating Mitophagy and Senescence.

Authors:  Eunjin Bae; Jin Hyun Kim; Myeong Hee Jung; Si Jung Jang; Tae Won Lee; Sehyun Jung; Seunghye Lee; Ha Nee Jang; Se-Ho Chang; Dong Jun Park
Journal:  Oxid Med Cell Longev       Date:  2020-11-23       Impact factor: 6.543

6.  Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: A CONSORT-compliant randomized controlled trial.

Authors:  Guang Ma; Min Li; Wei Teng; Zhaohui He; Xiaojv Zhai; Zhenhua Xia
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889

7.  Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention.

Authors:  H Zhang; H Fu; X Fu; J Zhang; P Zhang; S Yang; Z Zeng; N Fu; Z Guo
Journal:  BMC Nephrol       Date:  2021-06-02       Impact factor: 2.388

8.  Role of Nrf2 in Lipopolysaccharide-Induced Acute Kidney Injury: Protection by Human Umbilical Cord Blood Mononuclear Cells.

Authors:  Li-Xin Feng; Fei Zhao; Qian Liu; Jin-Cheng Peng; Xiang-Jie Duan; Ping Yan; Xi Wu; Hong-Shen Wang; Yin-Hao Deng; Shao-Bin Duan
Journal:  Oxid Med Cell Longev       Date:  2020-07-28       Impact factor: 6.543

9.  Cyclic RGD-Functionalized and Disulfide-Crosslinked Iodine-Rich Polymersomes as a Robust and Smart Theranostic Agent for Targeted CT Imaging and Chemotherapy of Tumor.

Authors:  Yan Zou; Yaohua Wei; Yinping Sun; Jie Bao; Feirong Yao; Zekun Li; Fenghua Meng; Chunhong Hu; Gert Storm; Zhiyuan Zhong
Journal:  Theranostics       Date:  2019-10-17       Impact factor: 11.556

Review 10.  The Pathophysiology and the Management of Radiocontrast-Induced Nephropathy.

Authors:  Eunjung Cho; Gang-Jee Ko
Journal:  Diagnostics (Basel)       Date:  2022-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.